Clinical relevance and druggability of sole reciprocal kinase fusions: A large‐scale study
Open Access
- 10 September 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (17) , e70191
Abstract
Background: Building on our prior work that RNA alternative splicing modulates the druggability of kinase fusions, this study probes the clinical significance of sole reciprocal fusions. These rare genomic arrangements, despite lacking kinase domains at the DNA level, demonstrated potential RNA‐level druggability in sporadic cases from our prior research.Methods: Utilizing the large‐scale multicenter approach, we performed RNA sequencing and clinical follow‐up to evaluate a broad spectrum of kinase fusions, including ALK, ROS1, RET, BRAF, NTRK, MET, NRG1, and EGFR, in 1943 patients.Results: Our findings revealed 51 instances (2.57%) of sole reciprocal fusions, predominantly in lung (57%), colorectal (14%), and glioma (10%) cancers. Comparative analysis with an MSKCC cohort confirmed the prevalence in diverse cancer types and identified unique fusion partners and chromosomal locales. Cross‐validation through RNA‐NGS and FISH authenticated the existence of functional kinase domains in subsets including ALK, ROS1, RET, and BRAF, which correlated with positive clinical responses to targeted kinase inhibitors (KIs). Conversely, fusions involving EGFR, NRG1, and NTRK1/2/3 generated nonfunctional transcripts, suggesting the need for alternative therapeutic interventions.Conclusion: This inaugural multicenter study introduces a novel algorithm for detecting and treating sole reciprocal fusions in advanced cancers, expanding the patient population potentially amenable to KIs.Keywords
This publication has 27 references indexed in Scilit:
- Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter studyMolecular Oncology, 2023
- Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancerMolecular Oncology, 2022
- Identification of MET fusions in solid tumors: A multicenter, large scale study in ChinaInternational Journal of Cancer, 2022
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patientsCell, 2022
- Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLCJournal of Thoracic Oncology, 2021
- Is Retention of the 5′ Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?Journal of Thoracic Oncology, 2020
- Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLCJournal of Thoracic Oncology, 2020
- RET fusions in solid tumorsCancer Treatment Reviews, 2019
- Tracing Oncogene Rearrangements in the Mutational History of Lung AdenocarcinomaCell, 2019
- Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancerJournal of Molecular Medicine, 2014